Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.49 |
| ▸ | RRM1 | P23921 | 1/20 | 0.47 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 6/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21107013 | 1.00 | MMP8 (0.49) | MMP8EPHX1RRM1DPP7MEN1 | |
| SCHEMBL23807034 | 0.98 | EPHX1 (0.50) | MMP8EPHX1RRM1DPP7ACHE | |
| SCHEMBL22799828 | 0.97 | DPP7 (0.50) | MMP8EPHX1RRM1DPP7MEN1 | |
| SCHEMBL25834708 | 0.93 | MEN1 (0.56) | MMP8MEN1KMT2ATHRBHTT | |
| SCHEMBL8404637 | 0.93 | MEN1 (0.56) | MMP8MEN1KMT2ATHRBHTT | |
| SCHEMBL24607334 | 0.93 | MAPT (0.50) | MMP8EPHX1DPP7MEN1KMT2A | |
| SCHEMBL23806827 | 0.93 | GNAI3 (0.47) | MMP8EPHX1RRM1DPP7MEN1 | |
| SCHEMBL23696456 | 0.92 | MEN1 (0.58) | MMP8DPP7MEN1KMT2ATHRB | |
| SCHEMBL22837704 | 0.92 | MEN1 (0.58) | MMP8DPP7MEN1KMT2ATHRB | |
| SCHEMBL22856581 | 0.92 | MEN1 (0.58) | MMP8DPP7MEN1KMT2ATHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-07-27 | — | — | US | disclosed |
| WO-2022147465-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-07-07 | — | — | WO | disclosed |
| WO-2022125804-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2022-06-16 | — | — | WO | disclosed |
| US-11117889-B1 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2021-09-14 | — | — | US | disclosed |
| WO-2020251971-A1 | SMARCA DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230234953-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | MMP8 901/4885EPHX1 1684/4885RRM1 3556/4885 |
| US-11117889-B1 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | MMP8 901/4885EPHX1 1684/4885RRM1 3556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.